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DISCUSSION
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome 
of pathologic immune activation characterized by clinical 
signs and symptoms of extreme inflammation.1
HLH can be primary (familial) or secondary (acquired). 
Primary HLH is caused by genetic mutations affecting the 
cytotoxic function of T lymphocytes and natural killer (NK) 
cells and typically presents in young children. Secondary 
(acquired) HLH occurs in the setting of infectious, 
malignant, rheumatologic, or metabolic conditions.2
In familial HLH certain mutations cause impaired cytotoxic 
function and lead to an uncontrolled inflammatory 
response with the activation and expansion of interferon 
gamma (IFN g)–producing T cells. High levels of IFN g 
lead to macrophage activation and overproduction of 
proinflammatory cytokines, which can cause severe tissue 
damage and organ failure. Mutations have been found in 
the following genes: PRF1, UNC13D (MUNC13-4), STX11, 
STXBP2, and MUNC18-2.2
The diagnosis of HLH is often delayed due to the rarity of 
the disease, the complexity of diagnosis criteria and the 
varying patterns of presentation seen in different patients. 
Any five of a combination of eight clinical and laboratory 
criteria diagnose HLH based on HLH-2004 protocol     
(Table 1)3
Treatment of HLH involves induction treatment with 
chemoimmunotherapy as recommended in the HLH-94 
protocol (figure 2), followed by maintenance treatment 
and hematopoietic stem cell transplant in those who have 
familiar, recurrent or HLH of unknown etiology.3
Despite its rarity we have seen about 5 cases of HLH at the 
Lehigh Valley Hospital over the past one year. We present 
here our first case of a pregnancy-associated HLH.
A Case of Pregnancy-associated Hemophagocytic Lymphohistiocytosis
Figure 1: Mechanics of cytotoxic function 
revealed by HLH-associated gene mutations.
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Hemophagocytic lymphohistiocytosis is a rare occurrence that is even rarer in pregnancy with only about 
12 cases described in the English literature as at 2015.4
HLH is characterized by high mortality. In pregnancy, those who respond to treatments suffer obstetric 
complications and often require induced abortion or premature birth.
A large number of reported pregnancy-related HLH were triggered by viral infection: EBV, parvovirus, VZV, 
HSV-2.5 In our patient, serology was positive for adenovirus IgG, but PCR was negative. It is likely that the 
HLH was induced by viral infection. 
Disease-specific treatment for HLH based on HLH-94 protocol involves induction with dexamethasone 
and etoposide (HLH-94)6. Chemotherapy is toxic to the fetus and thus cannot be given in pregnancy. 
Corticosteroid alone or in combination with IVIG have been have been successfully used in some reported 
cases.5
It is of interest that in a few reported cases, patients’ symptoms resolved and laboratory parameters 
improved after delivery, raising the assumption that pregnancy may increase risk in predisposed 
patients.4 However, mutation analysis shows no evidence of familial HLH in our patient and hence she 
likely has no predisposition. In her HLH was probably triggered by viral infection (adenovirus) and her 
pregnancy status was of unknown risk.
In patients with known predisposition to HLH, recurrent disease, or no clear precipitating cause 
allogeneic bone marrow transplant is recommended. Maintenance therapy with dexamethasone pulses, 
cyclosporine daily, and etoposide should be considered after induction if stem cell transplant is not 
immediately feasible.2
Because it was not clear-cut that HLH in our patient was viral-induced, maintenance treatments initially 
with dexamethasone pulses and etoposide and later with tacrolimus were considered.
A 33-year-old G2P1 Caucasian female presented at 27 weeks gestation with flu-like symptoms.  She reported one-week history of fever, chills, 
malaise and headache. A week before presentation, her two-year-old daughter had a febrile illness. A physical examination revealed an acutely 
ill female who was tachycardic (pulse 103) and mildly hypotensive (BP 96/53 mmHg). Initial laboratory evaluation revealed low platelet count (94 
thou/cmm), elevated lactate dehydrogenase (623u/L), mild transaminitis and elevated total bilirubin (3.1mg/dL). Empiric antibiotics were started. 
Within a few hours of admission, she developed hypoxic respiratory failure requiring mechanical ventilation. A chest X-ray showed left lower lobe 
infiltrate suspicious of pneumonia. She became hemodynamically unstable. Her declining hemodynamic and respiratory status led to fetal distress. 
Therefore, emergent pre-term C-section was performed. Multi organ failure developed, and three pressors were soon required for hemodynamic 
support. Because of her worsening hypoxemia, veno-venous extra corporeal membrane oxygenation (ECMO) was instituted. Continuous renal 
replacement therapy (CRRT) was started for worsening renal failure. Evaluation for infection, including culture of bronchial lavage, was negative. 
Viral serology was positive for adenovirus and EBV IgG, but polymerase chain reaction (PCR) was negative. Further laboratory evaluations revealed 
elevated ferritin >10,000 ng/mL, LDH 1500 u/L and triglyceride 1981 mg/dL. She also developed disseminated intravascular coagulation (DIC) 
requiring multiple infusion of cryoprecipitate and platelet. Due to suspicion for HLH an urgent bone 
marrow biopsy was performed, and soluble CD 25 level was checked. Bone marrow pathology 
revealed hemophagocytosis (figure 3). Soluble CD 25 was elevated, 5980 pg/mL (normal < 1033 pg/
mL). A computed tomography of the chest, abdomen and pelvis showed mild splenomegaly and no 
evidence of malignancy. She met HLH-2004 trial criteria with 6/8 findings for the diagnosis of HLH. 
After the diagnosis was established, treatment was started with corticosteroids (dexamethasone 10 
mg/m2). Etoposide was initially held due to renal failure and elevated bilirubin. It was later started 
with 25% of the dose established in HLH 94 protocol. A week later, she was extubated. CRRT was 
switched to intermittent hemodialysis. By the time she received her third dose of etoposide bilirubin 
and liver enzymes had improved, therefore she received 50% of protocol dose. She recovered 
fully and completed the induction therapy two months after her initial presentation. She started 
maintenance therapy with pulse dexamethasone and etoposide which was later switched to 
tacrolimus after her ferritin level normalized. Clinically the patient is doing well, so is her newborn. 
Figure 2: HLH-94 protocol for the treatment of HLH Figure 3: Bone marrow biopsy demonstrating 
hemophagocytosis
Table 1. Diagnostic Criteria for HLH Used        
in the HLH-2004 Trial
A Pathologic mutations of PRF1, UNC13D, Munc18-2, Rab27a, 
STX11, SH2D1A, or BIRC4
B
Five of the 8 criteria listed below are fulfilled
1.  Fever 38.50C
2.  Splenomgealy
3.  Cytopenias (affecting at least 2 of 3 lineages in the 
peripheral blood)
          a. Hemoglobin 9 g/dL (in infants 4 weeks: hemoglobin 10 g/dL)
          b. Platelets 100,000
          c. Neutrophils 100
4.  Hemophagocytosis in bone marrow, spleen, lymph 
nodes, or liver
5.  Low or absent NK-cell activity
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